Home > Haematology > ASH 2021 > Acute Myeloid Leukaemia > AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML

AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML

Presented By
Dr Hartmut Döhner, Universitätsklinikum Ulm, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 2, AMLSG 16-10
The final results of the phase 2 AMLSG 16-10 trial showed that younger and older patients with FLT3-ITD-mutated acute myeloid leukaemia (AML) benefitted from the addition of midostaurin to intensive chemotherapy. Furthermore, the occurrence of NPM1 mutations was a favourable prognostic factor. Older age, higher white blood cell (WBC) count, and higher FLT3-ITD allelic ratios increased the risk of unfavourable health outcomes [1]. Midostaurin is a first-generation, type I kinase inhibitor targeting FLT3-ITD and FLT3-TKD mutations [2]. The single-arm, phase 2 AMLSG 16-10 trial (NCT01477606) included patients with newly diagnosed, FLT3-ITD-mutated AML up to 70 years of age (n=440) to investigate midostaurin plus induction chemotherapy, followed by allogeneic haematopoietic cell transplantation (HCT) and 1-year mido...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on